Bulletin
Investor Alert

Edesa Biotech Inc.

NAS: EDSA

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Edesa Biotech Inc.

After Hours

 --Quotes are delayed by 20 min

May 20, 2022, 5:20 p.m.

EDSA
/zigman2/quotes/200172674/composite

$

2.05

Change

+0.23 +12.64%

Volume

Volume 2

Quotes are delayed by 20 min

/zigman2/quotes/200172674/composite

Previous close

$ 1.89

$ 1.82

Change

-0.07 -3.70%

Day low

Day high

$1.80

$1.89

Open

52 week low

52 week high

$1.72

$12.00

Open

Company Description

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its product candidate, EB01 is a non-steroidal, anti-inflammatory treatment for chronic all...

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its product candidate, EB01 is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis, a common, potentially debilitating condition and occupational illness. The company was founded on June 12, 2007 and is headquartered in Markham, Canada.

Valuation

Price to Book Ratio

7.51

Enterprise Value to EBITDA

-0.92

Efficiency

Liquidity

Current Ratio

8.29

Quick Ratio

8.29

Cash Ratio

5.37

Profitability

Return on Assets

-105.28

Return on Equity

-120.39

Return on Total Capital

-211.16

Capital Structure

Total Debt to Total Assets

0.68

Officers and Executives

Name Age Officer Since Title
Dr. Pardeep Nijhawan 49 2015 Chief Executive Officer, Secretary & Director
Dr. Michael Brooks 41 2015 Vice President- Corporate Development & Strategy
Ms. Kathi Niffenegger 64 2013 Chief Financial Officer
Dr. Blair Gordon - 2016 Vice President-Research & Development
Mr. Rajan Puri - 2021 Senior Vice President-Manufacturing

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
03/31/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		2,000   Acquisition at $2.99 per share. 5,980
03/30/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		2,000   6,100
03/30/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		2,000   6,100
03/30/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		2,000   Acquisition at $3.05 per share. 6,100
03/29/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		2,000   6,040
03/29/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		2,000   6,040
03/29/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		2,000   Acquisition at $3.02 per share. 6,040
03/18/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		2,000   7,700
03/18/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		2,000   7,700
03/18/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		2,000   Acquisition at $3.85 per share. 7,700
03/17/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		1,603   5,225
03/17/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		397   1,290
03/17/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		1,603   5,225
03/17/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		397   1,290
03/17/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		1,603   Acquisition at $3.26 per share. 5,225
03/17/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		397   Acquisition at $3.25 per share. 1,290
03/15/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		2,000   5,600
03/15/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		2,000   5,600
03/15/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		2,000   Acquisition at $2.8 per share. 5,600
03/14/2022 Michael Brooks
President 		1,250   3,487
03/14/2022 Michael Brooks
President 		1,250   3,487
03/14/2022 Michael Brooks
President 		1,250   Acquisition at $2.79 per share. 3,487
03/11/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		5,000   15,300
03/11/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		2,000   6,360
03/11/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		5,000   15,300
03/11/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		2,000   6,360
03/11/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		5,000   Acquisition at $3.06 per share. 15,300
03/11/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		2,000   Acquisition at $3.18 per share. 6,360
03/10/2022 Michael Brooks
President 		1,000   3,220
03/10/2022 Michael Brooks
President 		1,000   3,220
03/10/2022 Michael Brooks
President 		1,000   Acquisition at $3.22 per share. 3,220
03/09/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		1,500   4,575
03/09/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		1,500   4,575
03/09/2022 Pardeep Nijhawan
Chief Executive Officer; Director 		1,500   Acquisition at $3.05 per share. 4,575
/news/latest/company/us/edsa

MarketWatch News on EDSA

  3. Stellar Biotechnologies stock price target cut to $7 from $17 at Maxim Group

    7:50 a.m. Aug. 1, 2016

    - Tomi Kilgore

  4. Stellar Biotechnologies Gets a Positive Sign

    1:03 a.m. Feb. 26, 2016

    - Barron's Online

/news/nonmarketwatch/company/us/edsa

Other News on EDSA

  1. 10-Q: EDESA BIOTECH, INC.

    9:09 a.m. May 13, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  4. Edesa Biotech slips on ~$10M share offering

    8:19 a.m. March 22, 2022

    - Seeking Alpha

  5. 10-Q: EDESA BIOTECH, INC.

    10:08 a.m. Feb. 14, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  7. 10-K: EDESA BIOTECH, INC.

    5:58 p.m. Dec. 28, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  8. AG, FRO and WATT among pre market gainers

    8:33 a.m. Oct. 19, 2021

    - Seeking Alpha

  11. NNVC, RWLK and INDI among mid-day movers

    12:52 p.m. Sept. 21, 2021

    - Seeking Alpha

  13. ATER, GREE and BEST among mid-day movers

    1:51 p.m. Sept. 20, 2021

    - Seeking Alpha

  15. 10-Q: EDESA BIOTECH, INC.

    4:21 p.m. Aug. 13, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  16. Edesa Biotech EPS misses by $0.04

    8:02 a.m. Aug. 13, 2021

    - Seeking Alpha

  17. Edesa Biotech extends EB01 mid-stage dermatitis study to Canada

    9:04 a.m. July 13, 2021

    - Seeking Alpha

  18. GEO, GERN, SWBI and CVAC among premarket gainers

    8:19 a.m. June 18, 2021

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Edesa Biotech, Inc.

100 Spy Court

Markham, Ontario L3R 5H6

Phone

1 2898009600

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

09/2022

View SEC Filings

Revenue

N/A

Net Income

$-13.34M

Employees

16.00

Annual Report for EDSA

/news/pressrelease/company/us/edsa

Press Releases on EDSA

  3. Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results

    8:55 a.m. May 13, 2022

    - ACCESSWIRE

  5. Edesa Biotech Appoints Strategy Expert to Board of Directors

    9:01 a.m. March 29, 2022

    - ACCESSWIRE

  9. Edesa Biotech Reports Fiscal 1st Quarter 2022 Results

    10:01 a.m. Feb. 14, 2022

    - ACCESSWIRE

  10. Edesa Biotech to Join Ontario Bioscience Panel Discussion

    8:46 a.m. Jan. 26, 2022

    - ACCESSWIRE

  12. Opening to '22 Features Job Figures Friday

    4:42 p.m. Dec. 31, 2021

    - Baystreet.ca

  13. Edesa Biotech Reports Fiscal Year 2021 Results

    5:15 p.m. Dec. 28, 2021

    - ACCESSWIRE

  15. Edesa Biotech Extends COVID-19 Clinical Study to Poland

    8:02 a.m. Nov. 4, 2021

    - ACCESSWIRE

  21. Loading more headlines...
Link to MarketWatch's Slice.